The Food and Drug Administration has approved a new once-weekly injectable medication for Type 2 diabetes that clinical trials show produces fewer gastrointestinal side effects than existing treatments. The drug, marketed under the name Glucoriva, will be available by prescription starting in May.
In Phase 3 trials involving 8,000 patients, Glucoriva demonstrated comparable blood sugar control to leading competitors while reducing nausea and digestive complaints by nearly 40 percent.
